Duke logo

ECOG-ACRIN EAF151 for Glioblastoma - Clinical Trial

What is the Purpose of this Study?

We are doing this study to test whether the advanced perfusion MRI done prior to starting bevacizumab and a few weeks after starting bevacizumab can determine your response to the treatment better than the standard MRI performed at typical time points. The researchers want to see if this type of advanced MRI is better or the same as what is usually used for monitoring your brain cancer.

Bevacizumab is considered standard of care, meaning it is the normal approach to treating this kind of cancer.

What is the Condition Being Studied?

Brain cancer (glioblastoma or gliosarcoma)

Who Can Participate in the Study?

Adults over 18 years of age who
- Have histologically proven intracranial glioblastoma or gliosarcoma at initial surgery
- Have progression of disease assessed by local site using RANO criteria
- Are not pregnant or breast-feeding

Age Group
Adults

What is Involved?

If you agree to be in this study:
All research study participants will be treated for recurrent brain cancer with bevacizumab and will have two advanced perfusion MRI scans.
-- The first advanced MRI will be done just before your treatment starts with bevacizumab,
-- The second advanced MRI will be done between 12 and 25 days after you start your treatment with bevacizumab, within three days prior to your second dose.

Study Details

Full Title
ECOG-ACRIN EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00084094
NCT:NCT03115333
Phase
Phase N/A
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698